Skip to main content

Human/Mouse SUMO3 Antibody

R&D Systems, part of Bio-Techne | Catalog # AF2959

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AF2959
AF2959-SP

Key Product Details

Species Reactivity

Human, Mouse

Applications

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

E. coli-derived recombinant human SUMO3
Met1-Phe103
Accession # P55854

Specificity

Detects endogenous human and mouse proteins modified with SUMO3 in Western blots. In Western blots, less than 10% cross-reactivity with recombinant human SUMO2 and SUMO4 is observed, and less than 1% cross-reactivity with SUMO1 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human/Mouse SUMO3 Antibody

Detection of Human SUMO3 antibody by Western Blot.

Detection of Human SUMO3 by Western Blot.

Western blot shows lysates of A549 human lung carcinoma cell line, DU145 human prostate carcinoma cell line and mouse liver. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human/Mouse SUMO3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2959) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). A specific band was detected for SUMO3 at approximately 11 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 4.

Applications for Human/Mouse SUMO3 Antibody

Application
Recommended Usage

Western Blot

0.5 µg/mL
Sample: A549 human lung carcinoma cell line and DU145 human prostate carcinoma cell line
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: SUMO3

Small Ubiquitin-like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation. Unlike ubiquitination, which targets proteins for degradation, sumoylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability. All SUMO proteins share the conserved ubiquitin domain and the C‑terminal diglycine cleavage/attachment site. Human SUMO3, also known as SMT3A, is synthesized as a 103 amino acid (aa), 11.5 kDa propeptide that contains an 11 aa C‑terminal prosegment. Following prosegment cleavage, the C‑terminal glycine is enzymatically attached to a lysine on a target protein. Human SUMO3 shares 83% sequence identity with SUMO3 from mouse. SUMO3 also has very high sequence homology to SUMO2 and SUMO4, 87% and 75%, respectively. SUMO3 shares only 47% sequence identity to SUMO1.

Long Name

Small Ubiquitin-like Modifier 3

Alternate Names

SMT3A, SMT3H1

Entrez Gene IDs

6612 (Human)

Gene Symbol

SUMO3

UniProt

Additional SUMO3 Products

Product Documents for Human/Mouse SUMO3 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human/Mouse SUMO3 Antibody

For research use only

Loading...
Loading...
Loading...
Loading...